PDS Biotechnology Corporation announced positive results from Stage 1 of a National Cancer Institute (NCI)-led clinical trial for PDS01ADC, a novel immunotherapy treatment for metastatic colorectal cancer. The trial, utilizing a Simon two-stage design, exceeded its target response rate, triggering expansion into Stage 2 enrollment. This study evaluates PDS01ADC combined with floxuridine administered via hepatic artery infusion pump, and includes cohorts for cholangiocarcinoma and adrenocortical cancer as well.
The promising Stage 1 results are particularly noteworthy given the aggressive nature and high mortality rate associated with metastatic colorectal cancer. Current treatments often struggle to effectively manage the disease, particularly once it has spread. The achieved milestone suggests that PDS01ADC, designed to minimize systemic exposure to IL-12, may offer a more targeted approach to cytokine therapy without the typical limitations of toxicity. This could potentially translate to better outcomes for patients with this challenging cancer type.
The trial’s success in meeting the RECIST v1.1 criteria led to the expansion of the colorectal cancer cohort to a total of 22 participants. PDS01ADC is an antibody-drug conjugate designed to target tumor necrosis regions. This targeted approach aims to maximize efficacy while minimizing side effects, a critical factor in improving patient care. The other cohorts in the study, focusing on cholangiocarcinoma and adrenocortical cancer, are still in Stage 1 enrollment.
This positive development reinforces the potential of PDS01ADC as a viable treatment option for metastatic colorectal cancer. Successful completion of Stage 2 could pave the way for further clinical investigation and potential regulatory approval, ultimately offering new hope for patients facing this difficult diagnosis. This progress also bolsters PDS Biotech‘s position in the immunotherapy landscape and contributes to the broader advancement of targeted cancer therapies. The anticipated completion of enrollment for the colorectal cancer cohort by Q4 2025 marks a significant near-term milestone.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
